Pliant Therapeutics
Presença
Pliant Therapeutics é uma das ...
Pliant Therapeutics é uma empresa listada sob o símbolo PLRX (US).
Executivos
Veja o organograma con seus 32 executivos principais
Biografias mais buscadas da Pliant Therapeutics
- Bernard Coulie, Chief Executive Officer and Director
- Smital Shah, Director
- Hoyoung Huh, Chairman of the Board
Recentes movimentos de executivos em Pliant Therapeutics
- Mishima Gerhart, ingressou na Companhia como Chief Regulatory Officer (Notícia publicada em 17 de outubro de 2023).
- Minnie Kuo, ingressou na Companhia como Chief Development Officer (Notícia publicada em 17 de setembro de 2023).
Criar um alerta
para seguir os movimentos de executivos da Pliant Therapeutics.
Farmacêutica
Pliant Therapeutics possui 1.863 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
- Frontier Medicines acaba de anunciar uma arrecadação de fundos de 80 milhões de dólares. (publicado em 27 de fevereiro de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Pliant Therapeutics
- Pliant Therapeutics to Participate in BTIG Biotechnology Conference | Pliant Therapeutics, Inc.
- Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Proposed Public Offering of Common Stock | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial | Pliant Therapeutics, Inc.
- Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration | Pliant Therapeutics, Inc.
- Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 | Pliant Therapeutics, Inc.
- View more press releases Close
Redes sociais sobre Pliant Therapeutics
- Pliant Therapeutics na Wikipedia, Google News e Yahoo Finance
- Pliant Therapeutics na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Bernard Coulie 
Ligue para a Pliant Therapeutics em +1 910...
